Results 121 to 130 of about 1,734 (194)

Transplant Trial Watch [PDF]

Mentor, Keno, O’Callaghan, John M.
core   +2 more sources

Beyond Thresholds: CMV Replication Kinetics as Early Predictors of Clinical Risk in Transplant Recipients. [PDF]

Infect Drug Resist
Kleiboeker HL, Descourouez JL, Saddler C, Jorgenson MR.   +3 more
europepmc   +1 more source

A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for Cytomegalovirus (CMV) Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol. [PDF]

Cureus
Culpepper H, Overstreet M, Soliman K, Casey M, Rice T, Lively K, Scalea J, McGillicuddy J, Patel N, Taber D.   +9 more
europepmc   +1 more source

Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. [PDF]

Immunotherapy
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

Screening and characterization of novel chemical compounds inhibiting cytomegalovirus infection [PDF]

, 2019
Nahrevanian, Shahab
core   +1 more source

Current and Future Strategies for the Prevention and Treatment of Cytomegalovirus Infections in Transplantation. [PDF]

Clin Infect Dis
Heldman MR, Boeckh MJ, Limaye AP.
europepmc   +1 more source

Aim at the target: cytomegalovirus [PDF]

, 2016
Pattacini, Laura
core  

Cytomegalovirus Tegument Proteins and the Development of Novel Antiviral Therapeutics [PDF]

, 2013
Tomtishen, John Paul III
core   +2 more sources

CMV infections after HSCT: prophylaxis and treatment. [PDF]

Blood Res
Chung H.
europepmc   +1 more source

[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Xuan L, Huang H, Xu LP, Fu YW, Chen F, Wang Y, Wang SQ, Dong L, Wu JY, Wu DP.   +9 more
europepmc   +1 more source